OBJECTIVE: Adjuvant 17-hydroxyprogesterone caproate (17-OHPC) supplementation may improve health outcomes in women with a history of recurrent spontaneous preterm birth (SPTB) who received a history-indicated cerclage, but it is unclear whether 17-OHPC use is cost-effective in this setting. The aim of this study was to evaluate the cost-effectiveness of adjuvant 17-OHPC supplementation in preventing SPTB in women with a history-indicated (prophylactic cerclage). STUDY DESIGN: Baseline model parameters were sourced from randomized clinical trials and observational studies, and data was extracted for costs and outcomes of treatment. The primary outcome of interest is the number of preterm births averted by each strategy per 1,000 patients treated. Costs were discounted annually at 3%. Patients' outcomes were modeled for 80 years and incremental costeffectiveness ratios (ICER) were calculated from a payer perspective. The robustness of the results was performed by univariate and probabilistic sensitivity analyses by examining scatter plots of incremental costs and effectiveness. TreeAge Pro 2018 was used for data analysis. RESULTS: In the base case analysis, compared to prophylactic cerclage alone, adjuvant treatment with 17-OHPC was associated with lower incidence of preterm birth, and averted 40 more cases of SPTB per 1,000 patients treated, resulting in an incremental benefit of 3.26 QALYs and an ICER of 2,706 per QALY gained. Univariate sensitivity analysis showed findings to be robust under almost all scenarios. Probabilistic sensitivity analysis showed that there is a 58% probability that treatment with 17-OHPC was associated with a cost per QALY of less than $50,000. In 66% of Monte Carlo simulation of 10 million trials, adjuvant 17-OHPC was cost saving in comparison with prophylactic cerclage alone. CONCLUSION: This decision analysis demonstrates that adjuvant 17-OHPC was found to be cost effective and cost saving in treating women with a history of recurrent spontaneous preterm birth compared to prophylactic cerclage alone. OBJECTIVE: To determine factors affecting the risk for spontaneous preterm delivery (sPTD) in women presenting with preterm vaginal bleeding at 24+0 e 33+6 weeks of gestation. STUDY DESIGN: A retrospective cohort study of women with singleton pregnancies who presented with vaginal bleeding at a gestational age (GA) of 24+0 e 33+6 weeks in a single medical center. All women underwent vaginal evaluation for cervical pathology in addition to sonographic assessment for signs of placental abruption, placental distance from the internal os and cervical length (CL). Women with delivery due to placental abruption<24 hours from admission or women with any cervical pathology (e.g. cancer, dysplasia or polyps) were excluded. RESULTS: 1. Of 138 women, 111 (80.4%) met inclusion criteria and were divided into 3 groups according to bleeding etiology: 1) Low lying placenta (<1cm from the internal os or previa (N¼24)); 2) post-coital bleeding (N¼18); 3) Unknown origin (N¼69). Only 6 (5.4%) women were diagnosed with placental abruption upon delivery.
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2. All groups were comparable regarding GA at admission, the rate of past PTD, treatment with progesterone prior to admission and presence of uterine contractions at admission (Table) . However, women with a low lying placenta had a higher rate of past vaginal delivery (Table) .
3. KaplaneMeier survival curve demonstrated an association between the proportion of undelivered patients from admission and the etiology of vaginal bleeding, with post-coital bleeding affording the most favorable prognosis, and low lying placenta the worst prognosis (P¼0.013, Figure) .
4. Multivariate analysis demonstrated that factors predicting the risk for sPTD<37weeks were previous PTD (5.30, 1.16-24.28, P¼0.03), CL at admission (0.93, 0.89-0.98, P¼0.009) and low lying placenta (3.93, 1.18-13.13, P¼0.01). CONCLUSION: Several factors can predict the risk for sPTD in women presenting with vaginal bleeding at 24-33 weeks of gestation. Besides past PTD and CL, the etiology for vaginal bleeding was associated with the risk for sPTD and time-interval to delivery.
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